<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849797</url>
  </required_header>
  <id_info>
    <org_study_id>50370</org_study_id>
    <nct_id>NCT00849797</nct_id>
  </id_info>
  <brief_title>Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions</brief_title>
  <official_title>Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Oxcarbazepine 600 mg Tablet and Trileptal® Following a 600 mg Dose in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of a test
      formulation of oxcarbazepine tablets and Trileptal® tablets administered as a 1 x 600 mg dose
      under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Oxcarbazepine</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Oxcarbazepine</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - 10-hydroxy-carbazepine in Plasma</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf - 10-Hydroxy-Carbazepine Metabolite</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - 10-Hydroxy-Carbazepine Metabolite</measure>
    <time_frame>Blood samples collected over 48 hour period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oxcarbazepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trileptal®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxcarbazepine</intervention_name>
    <description>600 mg Tablet</description>
    <arm_group_label>Oxcarbazepine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trileptal®</intervention_name>
    <description>600 mg Tablet</description>
    <arm_group_label>Trileptal®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female, smoker or non-smoker, 18 years of age and older.

          -  BMI greater than or equal to 19.0 and less than or equal to 30.0 kg/m2

        Exclusion Criteria

        Subjects to whom any of the following applies will be excluded from the study:

          -  Clinically significant illnesses or surgery within 4 weeks of the administration of
             study medication.

          -  Any clinically significant abnormality or abnormal laboratory test results found
             during medical screening.

          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the
             subject from participating in the study.

          -  Positive testing for hepatitis B, hepatitis C or HIV at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or
             over 90mmHg; or heart rate less than 50 or over 100 bpm) at screening.

          -  History of significant alcohol abuse or drug abuse within one year prior to the
             screening visit.

          -  Regular use of alcohol within six months prior to the screening visit (more than 14
             units of alcohol per [1 Unit = 150 mL of wine or 360 mL of beer or 45 mL of 40%
             alcohol], or positive alcohol breath test at screening.

          -  Use of soft drugs (such as marijuana) within 3 months of the screening visit or hard
             drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year prior to the
             screening visit or positive urine drug screen at screening.

          -  History of allergic reactions to heparin, oxcarbazepine, carbamazepine, or other
             related drugs.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,
             imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days
             prior to the administration of the study medication.

          -  Use of an investigational drug or participation on an investigation study within 30
             days prior to dosing.

          -  Clinically significant history or presence of any gastrointestinal pathology (e.g.
             chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms
             (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to
             interfere with the absorption, distribution, metabolism, or excretion of the drug.

          -  Any clinically significant history or presence or neurological, endocrinal,
             cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic
             disease.

          -  Use of prescription medication within 14 days prior to administration of study
             medication or over-the-counter products (including natural food supplements, vitamins,
             garlic as a supplement) within 7 days prior to administration of study medication,
             except for topical products without systemic absorption.

          -  Difficulty to swallow study medication.

          -  Smoking more than 25 cigarettes per day.

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             Medical Sub-Investigator, could contraindicate the subject's participation in this
             study.

          -  A depot injection or an implant of any drug within 3 months prior to administration of
             study medication.

          -  Donation of plasma (500 mL) within 30 days prior to drug administration. Donation or
             loss of whole blood (excluding the volume of blood that will be drawn during the
             screening procedures of this study) prior to administration of the study medication as
             follows:

          -  50 mL to 300 mL of whole blood within 30 days or

          -  301 mL to 500 mL of whole blood within 45 days or

          -  more than 500 mL of whole blood within 56 days.

          -  Consumption of food or beverages containing grapefruit (e.g. fresh, canned or frozen)
             within 7 days prior to administration of the study medication.

          -  History or presence of atreoventricular (AV) block.

          -  Difficulty fasting or consuming the standard meals.

          -  Intolerance to venipunctures.

          -  Clinically significant history of renal, hepatic, or cardiovascular, tuberculosis,
             epilepsy, asthma, diabetes, psychosis, or glaucoma will not be eligible for this
             study.

          -  Positive urine pregnancy test at screening.

          -  Breast-feeding subject.

          -  Female subjects of child-bearing potential having unprotected sexual intercourse with
             any non-sterile male partner within 14 days prior to study drug administration.
             Acceptable methods of contraception:

          -  Intra-uterine contraceptive device (placed at least 4 weeks prior to study drug
             administration.

          -  Condom or diaphragm + spermicide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <results_first_submitted>July 2, 2009</results_first_submitted>
  <results_first_submitted_qc>July 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxcarbazepine</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oxcarbazepine (Test) First</title>
          <description>Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Trileptal® (Reference) First</title>
          <description>Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>bad veins</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout: One Week</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxcarbazepine (Test) First</title>
          <description>Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Trileptal® (Reference) First</title>
          <description>Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxcarbazepine</title>
            <description>Oxcarbazepine 600 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Trileptal®</title>
            <description>Trileptal® 600 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration - Oxcarbazepine in Plasma</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3537.63" spread="1333.09"/>
                    <measurement group_id="O2" value="3820.31" spread="1357.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>90.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>85.47</ci_lower_limit>
            <ci_upper_limit>96.60</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Oxcarbazepine</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxcarbazepine</title>
            <description>Oxcarbazepine 600 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Trileptal®</title>
            <description>Trileptal® 600 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Oxcarbazepine</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9679.79" spread="2371.03"/>
                    <measurement group_id="O2" value="9772.18" spread="2350.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>98.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.59</ci_lower_limit>
            <ci_upper_limit>100.66</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Oxcarbazepine</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxcarbazepine</title>
            <description>Oxcarbazepine 600 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Trileptal®</title>
            <description>Trileptal® 600 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Oxcarbazepine</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9445.55" spread="2327.24"/>
                    <measurement group_id="O2" value="9539.53" spread="2293.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>98.74</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.71</ci_lower_limit>
            <ci_upper_limit>100.80</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - 10-hydroxy-carbazepine in Plasma</title>
        <description>Informational Purposes Only</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxcarbazepine</title>
            <description>Oxcarbazepine 600 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Trileptal</title>
            <description>Trileptal® 600 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - 10-hydroxy-carbazepine in Plasma</title>
          <description>Informational Purposes Only</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9349.83" spread="1739.68"/>
                    <measurement group_id="O2" value="9517.52" spread="2034.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>98.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>95.66</ci_lower_limit>
            <ci_upper_limit>100.48</ci_upper_limit>
            <estimate_desc>Results presented for informational purposes only; metabolite not subjected to bioequivalence criteria.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf - 10-Hydroxy-Carbazepine Metabolite</title>
        <description>Informational Purposes Only</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxcarbazepine</title>
            <description>Oxcarbazepine 600 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Trileptal®</title>
            <description>Trileptal® 600 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - 10-Hydroxy-Carbazepine Metabolite</title>
          <description>Informational Purposes Only</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197864.34" spread="47069.89"/>
                    <measurement group_id="O2" value="196607.20" spread="43337.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>100.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.96</ci_lower_limit>
            <ci_upper_limit>101.64</ci_upper_limit>
            <estimate_desc>Results presented for informational purposes only, metabolite not subjected to bioequivalence criteria.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - 10-Hydroxy-Carbazepine Metabolite</title>
        <description>Informational Purposes Only</description>
        <time_frame>Blood samples collected over 48 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Oxcarbazepine</title>
            <description>Oxcarbazepine 600 mg Tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Trileptal®</title>
            <description>Trileptal® 600 mg Tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - 10-Hydroxy-Carbazepine Metabolite</title>
          <description>Informational Purposes Only</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179002.40" spread="39157.51"/>
                    <measurement group_id="O2" value="177979.76" spread="35506.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Test/Ref Ratio of LS Means x 100</param_type>
            <param_value>100.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.91</ci_lower_limit>
            <ci_upper_limit>101.27</ci_upper_limit>
            <estimate_desc>Results presented for informational purposes only; metabolite not subjected to bioequivalence criteria.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

